Three-dimensional tumor cell and tissue culture system

• US 5,580,781 A
• Filed: 04/06/1995
• Issued: 12/03/1996
• Est. Priority Date: 04/18/1986
• Status: Expired due to Fees

• Current Assignee: RegeneMed, Inc.
• Original Assignee: Advanced Tissue Sciences, Inc.
• Inventors: Naughton, Gail K., Naughton, Brian A.
• Primary Examiner(s): WONG, LESLIE A
• Application Number:
  US08/417,541
• Time in Patent Office: 607 Days
• Field of Search: 424/95, 424/177, 424/572, 424/529, 424/530, 424/572, 424/534, 435/240.2, 435/240.21, 435/240.23, 435/240.243, 435/29, 435/32, 435/1, 435/240.1
• US Class Current: 435/1.1
• CPC Class Codes: A61B 2010/0258 Marrow samples
• CPC Class Codes: A61B 90/00 Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges protective face masks A41D13/11; surgeon's or patient's gowns or dresses A41D13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M1/00
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3886 comprising two or more cell types
• CPC Class Codes: A61L 27/60 Materials for use in artificial skin
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/33 Insulin together with transferrin C12N2500/25; Insulin-like growth factors C12N2501/105
• CPC Class Codes: C12N 2501/335 Glucagon; Glucagon-like peptide [GLP]; Exendin
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2502/091 melanocytes
• CPC Class Codes: C12N 2502/094 keratinocytes
• CPC Class Codes: C12N 2502/1323 Adult fibroblasts
• CPC Class Codes: C12N 2503/04 Screening or testing on artificial tissues
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 2533/30 Synthetic polymers thermoreactive polymers, e.g. PNIPAm, C12N2539/10
• CPC Class Codes: C12N 2533/40 Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
• CPC Class Codes: C12N 2533/70 : Polysaccharides
• CPC Class Codes: C12N 5/0698 : Skin equivalents
• CPC Class Codes: Y10S 623/915 : Method or apparatus for preparing biological material

Abstract

The present invention relates to a three-dimensional cell culture system which can be used to culture a variety of different cells and tissues in vitro for prolonged periods of time. In accordance with the invention, cells derived from a desired tissue are inoculated and grown on a pre-established stromal support matrix. The stromal support matrix comprises stromal cells, such as fibroblasts actively growing on a three-dimensional matrix. Stromal cells may also include other cells found in loose connective tissue such as endothelial cells, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma, etc. The stromal matrix provides the support, growth factors, and regulatory factors necessary to sustain long-term active proliferation of cells in culture. When grown in this three-dimensional system, the proliferating cells mature and segregate properly to form components of adult tissues analogous to counterparts found in vivo.

Claims

1. A three-dimensional tumor culture, comprising tumor cells cultured on a living stromal tissue prepared in vitro, comprising stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells.

2. The three-dimensional cell culture of claim 1 in which the stromal cells are fibroblasts.

3. The three-dimensional cell culture of claim 1 in which the stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

4. The three-dimensional cell culture of claim 1 in which the framework is composed of a biodegradable material.

5. The three-dimensional cell culture of claim 4 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

6. The three-dimensional cell culture of claim 1 in which the framework is composed of a non-biodegradable material.

7. The three-dimensional cell culture of claim 6 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

8. The three-dimensional cell culture of claim 4, 5, 6 or 7 in which the framework is pre-coated with collagen.

9. The three-dimensional cell culture of claim 1, 2, 3, 4, 5, 6 or 7 in which the framework is a mesh.

10. The three-dimensional cell culture of claim 8 in which the framework is a mesh.

11. A method for culturing tumor cells in vitro, comprising culturing tumor cells inoculated onto a living stromal tissue prepared in vitro, comprising stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells.

12. The method according to claim 11 in which the stromal cells are fibroblasts.

13. The method according to claim 11 in which the stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

14. The method according to claim 11 in which the framework is composed of a biodegradable material.

15. The method according to claim 14 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

16. The method according to claim 11 in which the framework is composed of a non-biodegradable material.

17. The method according to claim 16 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

18. The method according to claim 14, 15, 16 or 17 in which the framework is pre-coated with collagen.

19. The method according to claim 11, 12, 13, 14, 15, 16 or 17 in which the framework is a mesh.

20. The method according to claim 18 in which the framework is a mesh.

21. A method for transplantation or implantation of tumor cells into non-human animals which comprises implanting in vivo the tumor cells cultured on a living stromal tissue prepared in vitro, comprising stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells so that a tumor is formed.

22. The method according to claim 21 in which the stromal cells are fibroblasts.

23. The method according to claim 21 in which the stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

24. The method according to claim 21 in which the framework is composed of a biodegradable material.

25. The method according to claim 24 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

26. The method according to claim 21 in which the framework is composed of a non-biodegradable material.

27. The method according to claim 26 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

28. The method according to claim 24, 25, 26 or 27 in which the framework is pre-coated with collagen.

29. The method according to claim 21, 22, 23, 24, 25, 26 or 27 in which the framework is a mesh.

30. The method according to claim 28 in which the framework is a mesh.

31. A method for testing the effect of a drug comprising:

(a) exposing a three-dimensional tumor cell culture to the drug, in which the three-dimensional cell culture comprises tumor cells grown on a living stromal tissue prepared in vitro, comprising stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells; and

(b) determining the effect of the drug on the cells in culture.

32. The method for testing the effect of a drug according to claim 31 in which the stromal cells are fibroblasts.

33. The method for testing the effect of a drug according to claim 31 in which the stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells or adipocytes.

34. The method for testing the effect of a drug according to claim 31 in which the framework is composed of a biodegradable material.

35. The method for testing the effect of a drug according to claim 34 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

36. The method for testing the effect of a drug according to claim 31 in which the framework is composed of a non-biodegradable material.

37. The method for testing the effect of a drug according to claim 36 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

38. The method for testing the effect of a drug according to claim 34, 35, 36 or 37 in which the framework is pre-coated with collagen.

39. The method according to claim 31, 32, 33, 34, 35, 36 or 37 in which the framework is a mesh.

40. The method according to claim 38 in which the framework is a mesh.

41. A method for diagnosing or monitoring a malignancy in a patient, comprising:

(a) inoculating tumor cells obtained from the patient onto a living stromal tissue prepared in vitro, comprising stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework composed of a biocompatible, non-living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells;

(b) culturing the inoculated living stromal tissue in a nutrient medium so that the inoculated cells proliferate in culture; and

(c) determining the presence of malignant cells in the proliferated cells in culture.

42. The method for diagnosing or monitoring a malignancy according to claim 41 in which the stromal cells are fibroblasts.

43. The method for diagnosing or monitoring a malignancy according to claim 41 in which the stromal cells are a combination of fibroblasts and endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma Cells, mast cells or adipocytes.

44. The method for diagnosing or monitoring a malignancy according to claim 41 in which the framework is composed of a biodegradable material.

45. The method for diagnosing or monitoring a malignancy according to claim 44 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.

46. The method for diagnosing or monitoring a malignancy according to claim 41 in which the framework is composed of a non-biodegradable material.

47. The method for diagnosing or monitoring a malignancy according to claim 46 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, or a nitrocellulose compound.

48. The method for diagnosing or monitoring a malignancy according to claim 44, 45, 46 or 47 in which the framework is pre-coated with collagen.

49. The method for diagnosing or monitoring a malignancy according to claim 41, 42, 43, 44, 45, 46 or 47 in which the framework is a mesh.

50. The method according to claim 48 in which the framework is a mesh.

51. The method for diagnosing or monitoring malignancy according to claim 41 in which the tumor cells are hematopoietic cells.

52. The method for diagnosing or monitoring a malignancy according to claim 41 in which the tumor cells are melanocyte or keratinocyte cells.

53. The method for diagnosing or monitoring a malignancy according to claim 41 in which the tumor cells are liver parenchymal cells.

54. The method for diagnosing or monitoring a malignancy according to claim 41 in which the tumor cells are pancreatic acinar cells.

55. The method for diagnosing or monitoring a malignancy according to claim 41 in which the tumor cells are kidney parenchymal cells.

56. The method for diagnosing or monitoring a malignancy according to claim 41 in which the tumor cells are mucosal epithelium cells.

57. A method for diagnosing or monitoring a malignancy in a patient comprising:

(a) inoculating astrocytes from a tumor cell sample obtained from the patient onto a living stromal tissue prepared in vitro comprising confluent endothelial cells attached to and substantially enveloping a framework composed of a biocompatible non living material formed into a three-dimensional structure having interstitial spaces bridged by the endothelial cells;

(b) inoculating further onto said astrocytes, neuron cells from the sample obtained from the patient;

(c) culturing the inoculated living stromal tissue in a nutrient medium so that the inoculated cells proliferate in culture; and

(d) determining the presence of malignant astrocyte cells in the proliferated cells in culture.

58. A method for diagnosing or monitoring a malignancy in a patient comprising

(a) inoculating astrocytes from a tumor cell sample obtained from the patient onto a living stromal tissue prepared in vitro comprising confluent endothelial cells attached to and substantially enveloping a framework composed of a biocompatible non-living material formed into a three-dimensional structure having interstitial spaces bridged by the endothelial cells;

(b) inoculating further onto said astrocytes, neuron cells from the sample obtained from the patient;

(c) culturing the inoculated living stromal tissue in a nutrient medium so that the inoculated cells proliferate in culture; and

(d) determining the presence of malignant neuron cells in the proliferated cells in culture.